Background: Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent. Administration by continuous infusion and hematopoietic support have rendered dose intensification regimens possible by reducing both hematologic and non-hematologic toxicities. The optimal dose and schedule of ifosfamide when given at high doses remain to be defined. In a previous phase I study, we demonstrated the feasibility of a continuous infusion (c.i.) high-dose ifosfamide (HDI) regimen in the ambulatory setting for patients with advanced solid tumors. The objective of the present phase II study was to assess the antitumor activity and toxicity of such a schedule in patients with advanced pretreated STS.
Introduction
Therapeutic strategies in advanced and/or metastatic soft tissue sarcomas (STS) have been complicated by the demonstrated chemoresistance of these tumors to many forms of chemotherapy. Combinations of doxorubicin and ifosfamide, the most active agents in STS, have been extensively studied; improved response rates have been reported with some of these regimens, but often associated with increased toxicity [1] . All of the published phase III studies that have compared combination chemotherapy with single-agent doxorubicin failed to obtain a benefit for overall survival, with median survival time rarely exceeding 12 months [2] . One avenue to explore is dose-intensification of known active agents, of importance, sarcomas represent an attractive clinical model system for dose-response and dose intensity investigation. In vitro, several sarcoma cell lines exhibit a log-linear cell-kill relationship to chemotherapy dose, best established for alkylating agents [3] , while a body of clinical data supports the existence of a doseresponse correlation for doxorubicin against sarcomas [1] . Given the demonstrated single-agent activity of ifosfamide in pretreated advanced STS [4] [5] [6] [7] and its proven superiority over equitoxic doses of cyclophosphamide [8] , dose escalation of this drug has also been studied. Recent evidence indicates a strong dose-response relationship for ifosfamide in STS, also suggesting that delivery of this agent at high doses can often circumvent resistance to standard doses [5] [6] [7] [9] [10] [11] . However, the optimal ifosfamide dose and schedule remain to be determined. Patients who have either failed or relapsed following anthracycline-based chemotherapy are primary candidates for such investigational studies.
In a previous pilot study, our group tested the feasibility of an ambulatory treatment with a four-day schedule of c.i. high-dose ifosfamide (HDI) with mesna equidose and granulocyte colony-stimulating factor (G-CSF) support, on 32 patients with advanced solid tumors. At 16 g/m 2 the dose-limiting toxicity was renal, with two of the five treated patients developing renal failure; ifosfamide at 15 g/m 2 /course was identified as the maximally tolerable dose. At this latter dose level, non-hematological toxicity was acceptable, with satisfactory patient compliance [12] . An overall OR rate of 31% was observed in the 29 assessable patients, with one complete and eight partial responses; in the group of STS patients, five major responses were obtained (42%). Thus, to verify the activity of such a regimen against STS, we performed a phase II study of HDI by c.i. with mesna uroprotection and hematopietic support in patients with advanced and/or metastatic disease who had been treated with anthracycline-based chemotherapy.
Patients and methods
Patients with measurable metastatic or unrescctable locoregional recurrent, histologically proven STS, were enrolled. It was required that they have progressive disease after at least one prior anthracyclinebased chemotherapy regimen. Adequate renal (serum creatinine level ;£ 150 mmol/1), hepatic (bilirubin level $20 mmol/1), and bone marrow (leukocyte count > 3.5 x 10 9 /l and platelet count > 100 x 10 9 /l) function was required. Ifosfamide was administered at a dose of 3.5 g/ m 2 /day over four consecutive days by c.i. (total dose 14 g/m 2 /cycle), as previously described [12, 13] . One-third of the daily drug dose was given intravenously over six hours, then the c l. ifosfamide was administered through a portable infusion pump. Mesna was infused at equimolar doses along with ifosfamide, both in the bolus and c.i. administration. An additional 3.5 g/m 2 /day of mesna was given on day 5, due to its brief half-life. Treatment was given in an outpatient regimen in most patients (89%). G-CSF support was given from day 6 to day 12 as a daily subcutaneous injection of 200 ug. Courses were repeated every three weeks. Treatment was stopped in instances of WHO grade 3-4 neurologic or renal toxicity; bicarbonate infusion was performed in case of severe metabolic acidosis. Ifosfamide was reduced by 20% for subsequent cycles in case of sepsis that required hospitalization and parenteral antibiotics.
Toxicity was monitored by clinical and laboratory evaluations on day 21 of each cycle; criteria were those of WHO [14] . A complete blood cell count was performed weekly; all patients underwent blood and urinary renal function tests before each cycle and on the fourth day of the ifosfamide infusion. Responses were evaluated after every two cycles of chemotherapy, with repeated clinical and appropriate radiologic assessments based on the extent of the disease defined at presentation, according to WHO criteria [15] . Response duration was computed from the initiation of treatment to the first evidence of progressive disease for all responsive patients. Survival was measured from the first day of treatment to death or last patient observation.
Results
From December 1993 to April 1996, a total of 38 adult STS patients entered this phase II study (Table 1 ). All patients had been previously exposed to anthracycline for relapsed and/or metastatic disease, and 28 of them (74%) were also pretreated with ifosfamide at standard doses, as part of an ifosfamide-containing regimen (ifosfamide 9 g/m 2 and epidoxorubicin 110 mg/m 2 ). Treatment was well tolerated; all patients were able to receive at least 3 cycles of therapy; the median number of cycles given was 4 (range 3-6 per patient). There were no treatment-related deaths. The major dose-limiting toxicity was hematologic, which required treatment delay in 14 (9%) of 159 cycles administered (for one and two weeks in 12 and two patients, respectively). Grade 3 leukoneutropenia was documented in 45% of patients and in 56% of all cycles, despite G-CSF support. Grade 4 neutropenia occurred in six patients (after the first course in two and after three cycles in the other four); four patients (10%) experienced febrile neutropenic episodes during six (4%) of 159 cycles, requiring hospitalization and parenteral antibiotics. Seven patients developed grade 3-4 thrombocytopenia, four of whom required platelet transfusion. Non-hematologic toxicities were acceptable. Eight episodes of neurotoxicity occurred in six patients (16%), four during the first course (grade 1-2) and two after the third cycle of HDI (grade 3). Symptoms (somnolence, confusion, hallucinations) developed on the second or third day of therapy, and in all cases disappeared within 24-48 hours after cessation of treatment. In one patient ifosfamide infusion was interrupted on day 2 of the second cycle for 24 hours and then restarted without evidence of neurologic effects on subsequent days, while in three patients treatment was definitively stopped at the end of the third cycle. Renal toxicity was significant in a 67-year-old CR (V.)
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2 (17) 6 (16) 2 (7) OR (%) male patient treated for a large relapse of retroperitoneal leiomyosarcoma with lung metastases, who, during the third cycle of HDI, developed acute renal failure with severe metabolic acidosis. No symptoms of central nervous system toxicity were observed in this patient, in whom renal failure remained chronic up to his death after five months due to disease progression. Mild and transient metabolic acidosis was documented in 38% of patients and 25% of cycles; in no case was intravenous bicarbonate replacement required. Glicosuria and proteinuria were observed in 13% and 16% of patients, respectively; hypokaliemia occurred in eight patients, two of whom required intravenous potassium replacement. Subclinical serum electrolyte abnormalities were detectable during therapy in 63% of cases, always spontaneously reversible.
Response to HDI according to disease characteristics is shown in Table 2 . Fifteen of 38 assessable patients achieved a major response, for a response rate of 39% (95% CI: 26%-55%), with one complete and 14 partial remissions. In addition, 17 patients (45%) had stable disease and six patients (16%) had disease progression. Complete response was achieved after four courses in a male patient with lung metastasis by malignant fibrous histiocytoma of the left upper limb, who did not respond to his previous chemotherapeutic treatment (five courses of epidoxorubicin plus standard-dose ifosfamide). The clinical response, pathologically confirmed, lasted 21 + months, after which the disease relapsed in the left lung. The patient then underwent surgery again, and is presently disease-free at 30 months of follow-up evaluation. Of the 14 partial responders, 12 (86%) entered the study affected with lung metastases only and two with locoregional disease. After two to four cycles of therapy, five patients with lung metastases as the only site of metastatic disease underwent metastasectomy after obtaining a partial remission. One patient is living and disease-free after 12 months; two other patients had relapses in the lung at nine and 10 months and are still living with disease, and the other two died of cerebral metastases at four and eight months.
All but one of the responder patients had previously received ifosfamide at standard doses (9 g/m 2 /cycle), combined with epidoxorubicin. The more responsive histologic subtypes appeared to be synovial sarcoma and malignant fibrous histiocytoma (response rate of 75% and 64%, respectively). There were no responders among the nine patients with leiomyosarcoma; five of them had stable disease lasting from four to six months (median five months) and four had progression of disease. The median time for response was 40 days (range 21-60 days, two to three courses); median response durations for major responses and stable diseases were nine months (range 5-21+ months) and six months (range 4-14+ months), respectively. The median overall survival was 13 months (range 6-30+ months).
Discussion
Results of the present phase II study confirm that HDI is feasible and active in pretreated STS patients, producing major responses in 39% of cases. All but one responder patients in our study had progressed after receiving standard dose ifosfamide in association with epidoxirubicin; 87% of them (13 of 15) had lung metastases as the only site of metastatic disease, six of which underwent successful salvage surgery. These findings provide further evidence to a real capability of HDI to circumvent resistance to both previous anthracycline and low dose ifosfamide, as first suggested by Elias et al. [9] and recently confirmed in the report of Le Cesne et al. [10] . In addition, the high sensitivity of lung metastases by STS to HDI is of major interest in an era in which an increasing number of patients is able to be rendered disease-free over prolonged periods through pulmonary metastasectomy [16] [17] [18] . The non-hematologic toxicities encountered in this study were lower than previously reported with HDI at similar dosages [9] [10] [11] . It is our belief that these well-known dose-limiting side effects can be minimized in the majority of patients if strict attention is paid to adequate hydration and meticulous monitoring of renal and neurologic toxicity. In the present study, as well as in our previous experiences [12, 13] the system adopted of an ambulatory regimen by portable infusion pumps proved adequate to this end point, and encouraged good patient compliance as well.
Our and other available data on HDI convincingly suggest a dose-response relationship for ifosfamide in STS, and clinical results are promising. Ifosfamide at doses higher than 12 g/m 2 /course is capable of producing overall response rates of 17% to 45% in patients with advanced STS, refractory to anthracycline-containing regimens and mostly failed prior conventional-dose ifosfamide therapy. These findings represent a significant improvement over results achievable with standard-dose ifosfamide and compare favorably with those reported with more aggressive polichemotherapeutic regimens available today. However, it should be pointed out that all published data on HDI in STS are uncontrolled and schedule differences significantly confound analysis of the dose-response relationship. The challenge remains to determine the dose and schedule for ifosfamide that are both most effective and acceptably tolerable. While there is a body of evidence in support of the capability of the c.i. schedule to decrease both renal and central nervous system toxicity [5, 9, 10, 12] , many retrospective studies suggest that repeated short daily infusions of ifosfamide over four to five days may by superior to prolonged c.i. for the same total dose [5, 6, 11] . The impact of ifosfamide schedule variations on drug-related toxicity and activity need to be determined in controlled clinical trials. In addition, the activity of single-agent HDI as both first-line and adjuvant chemotherapy in STS has still to be compared to full doses anthracycline in randomized trials.
